F. Najjar

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).

R. Hustinx, G. Jerusalem, P. Rigo, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Positron emission tomography ( PET ) with 18 F-fluorodeoxyglucose ( 18 F-FDG ) for the staging of low-grade non-Hodgkin ' s lymphoma ( NHL ) *

R. Hustinx, G. Jerusalem, P. Rigo, 2005 .

Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.

G. Jerusalem, P. Rigo, G. Fillet, 2000, Haematologica.

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

G. Jerusalem, P. Rigo, G. Fillet, 1999, Blood.

Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.

G. Jerusalem, P. Rigo, G. Fillet, 2001, Haematologica.

Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma.

G. Jerusalem, P. Rigo, G. Fillet, 1999, Nuclear medicine communications.

Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).

R. Hustinx, G. Jerusalem, P. Rigo, 2001, Cancer biotherapy & radiopharmaceuticals.

An Appraisal of 18-Fluorodeoxyglucose Positron Emission Tomography for Melanoma Staging

R. Hustinx, P. Rigo, G. Piérard, 2000, Dermatology.

Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease

M. Moroni, C. Porta, G. Fillet, 1998 .

Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67

J. Foidart, R. Hustinx, P. Rigo, 2002, Nuclear medicine communications.